

# Study of Resistant Hypertension in Cases of Hypertension

HAFIZ MUHAMMAD KALEEM ULLAH<sup>1</sup>, MIRZA SARMAD MAJEED<sup>2</sup>, MUHAMMAD USMAN<sup>3</sup>

## ABSTRACT

**Aim:** To study the resistant hypertension in cases of hypertension.

**Methods:** This cross sectional consisted on 150 hypertensive patients and conducted at Department of Medicine, Mayo Hospital, Lahore from Sep 2015 to March 2016. Hypertension was considered as resistant hypertension when hypertensive patients managed with a combination of minimum 3 optimally dosed anti-hypertensive drugs of different classes, one of which ideally is a diuretic but having blood pressure 140/90mmHg (assessed on clinical examination, history and medical record) with patient's good compliance with medication.

**Results:** Total 150 hypertensive patients were selected for this study. Mean age of the patients was 56.45±9.63 years, mean Systolic blood pressure was 131.66±26.62 and mean diastolic blood pressure 83.90±14.6. Resistant hypertension rate was 39(26%) in 150 hypertensive patients.

**Conclusion:** Findings of this study revealed that female hypertensive patients were victim of resistant hypertension as compared to male hypertensive patient. Age group of 56 to 70 years was most affected age group.

**Keywords:** Resistant Hypertension, Obesity, Elderly, Pseudo resistance.

---

## INTRODUCTION

Globally hypertension (HT) is a one of the most common health problem<sup>1</sup>. The prevalence of hypertension in the developing world is on the increase. Hypertension is increasingly becoming common and mainly driven by demographic and epidemiological transition and changing life style among the people. The prevalence of hypertension varies from 15-35% in urban adult population of Asia as compared to rural population. This prevalence has been reported to be 17.9% for Pakistan<sup>2</sup>. HTN is very important risk factor for heart disease<sup>3</sup>.

Blood pressure (BP) above the goal (140/90 mm Hg) despite adherence to a combination of at least 3 optimally dosed anti-hypertensive drugs of different classes, one of which ideally is a diuretic is defined as Resistant hypertension<sup>4</sup>.

Patients with resistant HTN are more likely to have target organ damage and are at greater risk of heart failure, stroke, myocardial infarction and/or chronic kidney disease (CKD) as compared with cases who have more easily controlled HTN.<sup>5</sup> The high cardiovascular risk is attributable in part to long-standing, poorly controlled hypertension<sup>6</sup> and to the coexistence of other cardiovascular (CVD) risk factors, including diabetes mellitus, obesity, left ventricular hypertrophy (LVH), hyperlipidemia obstructive sleep apnea, and CKD. In one study by Sarwar et al reported that frequency of resistant HTN varies from 5-50%<sup>8</sup>. In another study reported

frequency of resistant HTN as 13% in hypertensive cases<sup>9</sup>.

As hypertension is a common problem and difficult to manage due to great morbidity and mortality associated with it. So a study is designed to find out the frequency of resistant hypertension in them. It may help us to decrease the morbidity and mortality of hypertension in our patients.

## MATERIAL AND METHODS

This is a cross sectional study. Total 150 patients fulfilling the inclusion/exclusion criteria presenting about patient Department Mayo Hospital, Lahore from Sep 2015 to March 2016 were included in this study. An approval was taken from institutional review committee and informed written consent was taken from every patient. All patients with hypertension, age range from 40-70 years either male or female were included in this study. Diagnosed cases of resistant hypertension (on history and medical record), patients already on treatment of resistant hypertension (on history & medical record) were excluded from the study.

Hypertension is diagnosed when systolic blood pressure is consistently elevated (4-5 readings on different occasions) above 140 mmHg or diastolic blood pressure is above 90 mmHg and having 6 months history of hypertension (history and medical record). Hypertension was considered as resistant hypertension when hypertensive patients managed with a combination of at least 3 optimally dosed antihypertensive medications of different classes, one of which ideally is a diuretic but having above goal

---

<sup>1,2,3</sup>HO Medicine, Mayo Hospital, Lahore  
Correspondence to Dr. Hafiz Muhammad Kaleem Ullah  
Email: mkaleemulah@gmail.com Cell: 03017444938

blood pressure i.e., 140/90mmHg (assessed on clinical examination, history and medical record) with patient's good compliance with medication.


The hypertensive patients were evaluated for resistant hypertension. Frequency of resistant hypertension in hypertensive patients were recorded on a pre-designed proforma along with demographic data of the patients.

All the data was entered and analyzed in an SPSS Version 16. Quantitative variable like age and systolic/diastolic blood pressure was recorded and presented in the form of mean±S.D. Qualitative data like gender, frequency of resistant hypertension in hypertensive patients was presented in the form of frequency and percentage. The data was stratified according to age and gender. Post stratification chi square test was applied to determine the significance. P.value ≤0.05 was considered as significant.

**RESULTS**

Total 150 hypertensive patients were selected for this study. Mean age of the patients was 56.45±9.63 years, mean Systolic blood pressure was 131.66±26.62 and mean diastolic blood pressure 83.90±14.6. Resistant hypertension rate was 39 (26%) in 150 hypertensive patients (Fig. 1).

Fig. 1: Frequency of hypertension



Stratification in relation to age was done and two group was made. Age group 40-55 years and age group 56-70 years. In age group 40-55 years, out of 55(36.67%) hypertensive patients, resistant hypertensive was noted in 14(25.45%) patients. Total 95(63.33%) patients belonged to age group 56-70 years and resistance hypertension was noted in

25(26.32%) patients. Statistically insignificant (P=1.00) association of age with resistance hypertension was noted. (Table 1)

Male hypertensives were 68(45.33%) and female hypertensives were 82(54.67%) and resistance hypertension was noted in 9(13.24%) and 30(36.59%) patients respectively. Significantly (P=0.001) higher rate of resistant hypertension was noted in female patients as compared to male patients (Table 2).

Table 1: Stratification for age

Age (years)	Resistant Hypertension		Total
	Yes	No	
40-55	14(25.45%)	41(74.55%)	55(36.67%)
56-70	25(26.32%)	70(73.68%)	95(63.33%)
Total	39(26%)	111(74%)	150

Tale 2: Stratification for gender

Gender	Resistant Hypertension		Total
	Yes	No	
Male	9(13.24%)	59(86.76%)	68(45.33%)
Female	30(36.59%)	52(63.41%)	82(54.67%)
Total	39(26%)	111(74%)	150

P value 0.001

**DISCUSSION**

About one billion individual affected by HTN globally<sup>1</sup>. Cardiovascular diseases significantly decreased after the introduction of anti-hypertensive medication. However, this medication failed to control the HTN in all the hypertensive individuals. BP goals are not attained in many of the individuals despite the simultaneous use of different anti-hypertensive therapies.

This condition has been defined by many terms like difficult to treat, refractory HRN, difficult to control HTN; however the term resistant hypertension seems to prevail<sup>1</sup>.

Several factors have been identified as contributors to resistant hypertension. Poor patient adherence, physician inertia, inadequate doses or inappropriate combinations of antihypertensive drugs, excess alcohol intake, and volume overload are some of the most common causes of resistance<sup>10</sup>. Secondary forms of hypertension represent another very important contributor to drug resistance. The list of secondary forms of hypertension is long and covers a large variety of conditions. Most of these conditions may result in resistance to pharmacologic therapy of hypertension<sup>10</sup>.

The management of patients with resistant hypertension requires a gratifying combination of clinical acumen and common sense. An extensive workup of all patients with uncontrolled hypertension is scientifically unsound, is very costly and requires

immense human and technical resources. Therefore, practicing physicians need to implement evidence-based medicine. The effective management of patients with resistant hypertension requires an appropriate combination of physiology and pharmacology, taking into account the unique characteristics of each case in order to tailor the therapeutic approach to the individual patient<sup>11-15</sup>.

In our study mean age of the patients was 58.30±8.72, mean Systolic blood pressure was 131.66±26.62 and mean diastolic blood pressure 83.90±14.6. Kumara WN et al<sup>16</sup> also concluded the favorable results. Mean systolic and diastolic blood pressure reported by Knight EL<sup>17</sup> was also comparable with my study. In present study resistant hypertension was found in 20% patients. In a cross-sectional study by Kumara WN et al<sup>16</sup> conducted at Colombo, resistant hypertension was found in 19.1% patients. Their findings were comparable with my study. A study of 53530 hypertensive patients by Kumbhani DJ et al<sup>3</sup> resistant hypertension was found in 12.7% patients. These findings were also in favour of my study.

## CONCLUSION

Findings of this study revealed that female hypertensive patients were victim of resistant hypertension as compared to male hypertensive patient. Age group of 56 to 70 years were most affected age group.

## REFERENCES

1. Erem C, Hacıhasanoglu A, Kocak M. Prevalence of prehypertension and hypertension and associated risk factors among Turkish adults: Trabzon Hypertension Study. *J Public Health* 2009;31(1):47-58.
2. Khan RMA, Saeed T, AWAN SR, Ahmad M. Public Awareness about Hypertension: Findings of a Kidney Day. *PJMHS*.2008;2(4):159-61
3. Kumbhani DJ, Steg PG, Cannon CP. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. *Eur Heart J* 2013;16:1204-14.
4. Calhoun DA, Jones D, Textor S. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension* 2008;51:1403–19.
5. Calhoun DA, Jones D, Textor S. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension* 2008;51:1403–19.
6. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. *Arch Intern Med* 2008;168:2340.
7. Feldman RD, Brass EP. From bad behaviour to bad biology: pitfalls and promises in the management of resistant hypertension. *Can J Cardiol*. 2013 May;29(5):549–56.
8. Sarwar MS, Islam MS, Al Baker SME, Hasnat A. Resistant hypertension: underlying causes and treatment. *Drug Res (Stuttg)*. 2013 May;63(5):217–23.
9. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. *Hypertension* 2011;57:1076–80.
10. Wildman RP, Gu D, Muntner P, Huang G, Chen J, Duan X, He J. Alcohol intake and hypertension subtypes in Chinese men. *J Hypertens*. 2005;23:737–743.
11. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. *J Clin Endocrinol Metab*. 2005;90:2110–2116.
12. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. *Mayo Clinic Proc*. 1981;56:354–360.
13. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. *Lancet*. 2005;366:665–675.
14. Moneva MH, Gomez-Sanchez CE. Pathophysiology of adrenal hypertension. *Semin Nephrol*. 2002;22:44–53.
15. Ferrari P. Cortisol and the renal handling of electrolytes: role of glucocorticoid-induced hypertension and bone disease. *Best Pract Res Clin Endocrinol Metab*. 2003;17:575–589.
16. Kumara WN, Perera T, Dissanayake M, Ranasinghe P, Constantine GR. Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country. *BMC research notes*. 2013;6(1):373.
17. Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. *Hypertension*. 2001 Oct;38(4):809–14.